Eu(III) and Eu(III) phosphonate doped hydroxyapatite: Photostable biological probe for targeting bone cancer

INOR 204

Laurence F. Bensaid-Geyer, laurencebensaid@hotmail.com1, Fang Yao, fy256@nyu.edu2, Racquel Z. LeGeros2, Tatyana Polenova, tpolenov@udel.edu3, and Lynn C. Francesconi, lfrances@hunter.cuny.edu4. (1) Department of Chemistry, Hunter College, 695 Park Av, new york, NY 10021, (2) Department of Biomaterials, New York University, College of Dentistry, 345 East 24th Street, New York, NY 10010, (3) Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, (4) Department of Chemistry, Hunter College and the Graduate Center of the City University of New York, 695 Park Avenue, New York, NY 10021
Radiolanthanide complexes with polyamino polyphosphonic acid ligands display high affinity for metabolizing bone and are used clinically for diagnosis and radiotherapy for bone metastases. 153Sm EDTMP is presently used for bone pain palliation and 166HoDOTMP is undergoing trials for radiotherapy of multiple myeloma. The mechanism of action for these radiotherapeutic drugs is unknown. In this work, a series of hydroxyapatite (HA) doped europium (Eu), and the complex of Eu with the ligand ethylenediaminetetramethylenephosphonic acid (EDTMP) have been adsorbed to HA and characterized. Due to its fluorescence, paramagnetism and relative non-toxicity, Eu(III) offers the possibility for monitoring and assessing the position of Eu in the HA mineral matrix and the adsorbed Eu-EDTMP local environment. As a final objective this material may be used as a vehicle for delivery of drugs to the bone.
 

General Inorganic Chemistry
7:00 PM-10:00 PM, Sunday, August 19, 2007 BCEC -- Exhibit Hall - B2, Poster

Division of Inorganic Chemistry

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007